Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp

Pettit, George R.; Herald, Cherry L.; Boyd, Michael R.; Leet, John E.; Dufresne, Claude; Doubek, Dennis L.; Schmidt, Jean M.; Cerny, Ronald L.; Hooper, John N. A.; Rützler, Klaus

doi:10.1021/jm00115a027

Cited by 175 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Critical to any research application of the screen is the remarkably high degree of reproducibility of the screening proflle of a given compound tested repetitively over time (6,13,27). (38,(45)(46)(47)54). Samples of the compounds were provided by George R. Pettit for study in the NCI screen.…”

mentioning

confidence: 99%

The NCI In Vitro Anticancer Drug Discovery Screen

Boyd¹

1997

Anticancer Drug Development Guide

Self Cite

222

202

View full text Add to dashboard Cite

mentioning

confidence: 99%

The NCI In Vitro Anticancer Drug Discovery Screen

Boyd¹

1997

Anticancer Drug Development Guide

Self Cite

222

202

View full text Add to dashboard Cite

“…18 During the 1990s, the US National Cancer Institute led attempts at aquaculture, but these were ultimately unsuccessful. 19 The total synthesis of halichondrin B was achieved by Kishi and colleagues at Harvard in 1992, and Eisai, a Japanese pharmaceutical company, began testing it as an anticancer agent. 20 Biological activity was shown to reside in the macrocyclic lactone C1-C8 moiety, located on the right half of the molecule.…”

Section: Preclinical Development Discovery and Synthesismentioning

confidence: 99%

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer

Menis

Twelves

2011

BCTT

View full text Add to dashboard Cite

Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used in this setting, but with little evidence of clinically relevant benefit, and none have previously shown improved survival. Eribulin (Halaven ® ) is a nontaxane tubulin-binding agent with a novel mode of action, and was recently approved by the European Medicines Agency and US Food and Drug Agency as a single agent for patients with heavily pretreated metastatic breast cancer. This review provides an overview of the discovery, and preclinical and clinical development of eribulin, culminating in the recently published EMBRACE metastatic breast cancer study.

show abstract

“…Il fallut attendre 1989 pour line et y détecte une puissante activité antitumorale. Une nouvelle récolte de 220 kg d'éponges est effectuée en 1985, mais ce n'est qu'en 1991 que sont réalisées la purification et l'identification des deux composés actifs (Homohalichondrine B et Halichondrine B), présents à très faibles concentrations [20]. En 1986, D. Uemura et Y. Hirata avaient déjà isolé, à partir de 600 kg de Halichondria okadai (Halichondridae), plusieurs composés cytotoxiques similaires qu'ils avaient nommés halichondrines.…”

Section: Les Halichondrinesunclassified